Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Receivables (2019 - 2025)

Biodesix (BDSX) has disclosed Change in Receivables for 7 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 460.44% year-over-year to -$3.6 million, compared with a TTM value of $531000.0 through Dec 2025, down 70.68%, and an annual FY2025 reading of $531000.0, down 70.68% over the prior year.
  • Change in Receivables was -$3.6 million for Q4 2025 at Biodesix, down from $5.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.2 million in Q3 2025 and bottomed at -$13.1 million in Q2 2021.
  • Average Change in Receivables over 5 years is -$144650.0, with a median of $201500.0 recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 5764.94% in 2021, then skyrocketed 7003.03% in 2024.
  • Year by year, Change in Receivables stood at $873000.0 in 2021, then dropped by 15.69% to $736000.0 in 2022, then soared by 380.98% to $3.5 million in 2023, then tumbled by 71.72% to $1.0 million in 2024, then tumbled by 460.44% to -$3.6 million in 2025.
  • Business Quant data shows Change in Receivables for BDSX at -$3.6 million in Q4 2025, $5.2 million in Q3 2025, and -$181000.0 in Q2 2025.